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Abstract | Evidence indicates that anatomical and physiological phenotypes of hypertrophic 
cardiomyopathy (HCM) stem from genetically-mediated, inefficient cardiomyocyte energy 
utilization, and subsequent cellular energy depletion. However, HCM often presents 
clinically with normal left ventricular (LV) systolic function or hyperkinesia. If energy 
inefficiency is a feature of HCM, why is it not manifest as resting LV systolic dysfunction? 
In this Perspectives article, we focus on an idiosyncratic form of reversible systolic 
dysfunction provoked by LV obstruction that we have previously termed the ‘lobster claw 
abnormality’ — a mid-systolic drop in LV Doppler ejection velocities.  In obstructive HCM 
it explains the mid-systolic closure of the aortic valve, the bifid aortic pulse, and why patients 
cannot increase stroke volume with exercise. This phenomenon is characteristic of a broader 
phenomenon in HCM that we have termed dynamic systolic dysfunction. It underlies the 
development of apical aneurysms, and rare occurrence of cardiogenic shock after obstruction. 
We posit that dynamic systolic dysfunction is a manifestation of inefficient cardiomyocyte 
energy utilization. Systolic dysfunction is clinically inapparent at rest.  However, it becomes 
overt through the mechanism of afterload mismatch when LV outflow obstruction is imposed   
Energetic insufficiency is also present in nonobstructive HCM. This paradigm suggests new 
therapies. Other pathways that might be central to HCM, such as myofilament Ca2+ 
hypersensitivity, and enhanced late Na+ current, are discussed. 
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Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with a prevalence 
of at least 1 in 500. Presentation is highly variable even within families, and although the 
majority of affected individuals lead a normal life, some develop severe, progressive heart 
failure symptoms, angina, or arrhythmia, and others die suddenly, either with or without 
previous symptoms. Left ventricular outflow tract (LVOT) obstruction occurs in two-thirds of 
patients either at rest or after provocation and can be improved by negatively inotropic drugs, 
surgical septal myectomy, or alcohol septal ablation1. Patients judged to be at high risk of 
sudden death (SCD) from ventricular fibrillation can be treated with an implanted 
defibrillator, most often as primary prevention, or for secondary prevention after surviving a 
potentially lethal ventricular arrhythmia2,3. 
 A crucial advance in our understanding of HCM was made in 1990 with the first 
report of a disease-associated mutation4. Subsequently, multiple disease-associated mutations 
have been discovered, most coding for sarcomeric proteins5. Mutations in multiple genes, 
encoding sarcomeric or nonsarcomeric proteins, lead to similar clinical manifestations; this 
observation gives hope that understanding the final common pathways that link known 
disparate mutations might lead to new and widely applicable therapies. Most of the mutations 
act as dominant negatives; they produce poisoned peptides, in which the mutant polypeptide 
produced disrupts the activity of the wild-type gene. An exception is the truncation mutations 
in MYBPC3 in which haploinsufficiency (a reduction in protein production) has been shown. 
In myectomy specimens from patients with an MYBPC3 truncation mutation, protein content 
was reduced by 24–33% compared with transplant donor, or non-MYBPC3 myectomy 
specimens6,7. 
 In vitro experiments on preparations from mutant HCM cardiomyocytes have 
produced strikingly contrasting results; both gain and loss of contractile function have 
variously been demonstrated8. See, for example, the compilation of disparate results 
 4 
published just for the R403Q mutation in MYH7, which encodes myosin-7 the cardiac 
β-myosin heavy chain9. Force generation with exposure to Ca2+ and the degree of leftward 
displacement (in most mutations) of force–Ca2+ curves is the method of determination. The 
difference between experiments might depend on intrinsic differences in the mutations, but 
also on the wide variety of experimental models used. Early experiments with the myosin 
heavy chain mutant R403Q showed loss of function, leading to the hypothesis that 
hypertrophy was a compensation for decreased force generation; others have shown increased 
sensitivity. Subsequent work with thin filament mutations showed increased Ca2+ sensitivity 
of force generation. 
 Despite the bewildering array of differing functional results, two pathophysiological 
pathways from sarcomeric mutations to a HCM phenotype have been consistently 
experimentally validated: first, inefficient energy utilization (energy wasting for tension 
development) and, second, increased myofilament Ca2+ sensitivity. In this Perspectives 
article, we focus primarily on the energy depletion hypothesis, but we also summarize the 
evidence for Ca2+ sensitization, and discuss how the two theories overlap. Increasing 
evidence indicates that energy depletion has an important role in the development of 
hypertrophy and in the wider pathophysiology of HCM9-15. We summarize this evidence, and 
then discuss the phenotypic manifestations of energy depletion in three realms of cardiac 
function: diastolic dysfunction, dynamic systolic dysfunction (especially against imposed 
afterload), and arrhythmogenesis. In particular, we show how patients with HCM experience 
a highly idiosyncratic form of systolic dysfunction, which we posit is best explained by 
inefficient utilization of energy. 
 
 
Energy Depletion, HCM and Diastole  
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The theory that the failing heart is running out of fuel is a longstanding one, going back to the 
early twentieth century11. The energy turnover of the normal heart can only be described as 
extravagant. The daily cardiac turnover of ATP, an astonishing 6 kg, is very many times the 
mass of the heart itself, and its myocardial ATP pool16. In <10–15 s, the total amount of ATP 
present within a myocyte is consumed by myocardial work and requires constant 
replenishment17. High energy needs make the myocardium sensitive to genetic and acquired 
perturbations in energy supply, and to inefficiency in its utilization, which result in the HCM 
phenotype in some patients12,13. The rationale for inefficient energy utilization as a cause of 
the HCM phenotype rests on several lines of evidence. 
 First, high-energy phosphate metabolism can be assessed in vivo in the heart using 
31P-magnetic resonance (MR) spectroscopy. Investigators compared the cardiac 
phosphocreatine (PCr) to ATP ratio in 31 patients harbouring mutations in the genes for 
either β-myosin heavy chain, cardiac troponin T, or myosin-binding protein C, and in 24 
control individuals. The PCr/ATP ratio was reduced in the patients with HCM by 30% 
relative to controls, and the reduction was of a similar magnitude in all three disease-gene 
groups, and not related to the degree or presence of hypertrophy13,17. ATP is produced in the 
mitochondria, but is used elsewhere, mainly by sarcomeric proteins and ion transporters. PCr, 
the most abundant high-energy phosphate in the heart, acts as an energy shuttle and as an 
energetic reserve, moving high-energy phosphate from the mitochondria to sites of 
utilization. In heart failure, cytosolic levels of ATP are generally zealously maintained, 
whereas PCr levels fall18,19. 
 Second, PET scanning using clearance of 11C-acetate as a semiquantitative measure of 
myocardial oxygen consumption has shown reduced consumption in patients with HCM as 
well as genetic carriers17,21,22. However, myocardial stroke work was reduced to an even 
greater extent than oxygen consumption; myocardial efficiency (the ratio of stroke work to 
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myocardial oxygen consumption) was, therefore, decreased. A combined in vitro and in vivo 
study using tissue of genotype-positive patients with HCM, and PET and cardiac MR scans, 
revealed an increase in energy tension–cost based on an imbalance between force-generating 
capacity and ATPase activity9,14. 
 Third, HCM phenocopies, caused by nonsarcomeric protein mutations can develop 
hypertrophy that resembles HCM, and also have similar flaws in cellular energetics. 
Examples are a mutation in the γ2 subunit of 5′ AMP-activated protein kinase (AMPK; 
known as the ‘cellular thermostat’ because of its central role in energy sensing and 
regulation) that was found to cause an HCM-like familial syndrome23,24. Similarly, 
maternally-inherited HCM owing to mutations in mitochondrial tRNA have been described25, 
with demonstrated defects in oxidative metabolism; all three respiratory chain complexes 
tested showed reduced activity. Abnormal mitochondrial electron microscopic morphology 
with disordered function have been described in HCM26,27. Patients with Friedreich ataxia, an 
autosomal recessive neurological disorder, also develop a syndrome of otherwise unexplained 
left ventricular hypertrophy. Mutations in the frataxin gene (FXN) result in reduced protein 
levels, leading to insufficient biosynthesis of iron–sulphur clusters that are required for 
mitochondrial electron transport and, therefore, ATP generation28. Moreover, two groups 
have shown impaired myocardial energetics with MR spectroscopy in patients with 
Friedreich ataxia associated with hypertrophic heart disease29,30. 
 Fourth, energy depletion is hypothesized to allow an increase in cytosolic Ca2+ that 
might mediate an upregulation of transcriptional processes that result in hypertrophy12. MR 
spectroscopy has shown that the observed levels of energetic depletion in HCM could 
compromise sarco/endoplasmic reticulum calcium ATPase (SERCA), that transports Ca2+ 
from the cytosol into the sarcoplasmic reticulum, because of the very high obligate energy 
requirements of this ion transporter8. Dysregulation of Ca2+ cycling and elevation of 
 7 
intracellular Ca2+ has been shown in HCM cardiomyocytes derived from induced pluripotent 
stem cells (iPSCs). Sustained elevation of Ca2+ is a known trigger for activation of 
calcineurin, which is an effector of hypertrophy. In iPSC-derived HCM myocytes, inhibition 
of calcineurin, and also of cellular Ca2+ inflow by verapamil, reduced hypertrophy32. 
 Multiple converging, genetically-mediated metabolic pathways that are associated 
with an increased energetic cost of tension development, therefore, lead to the hypertrophic 
phenotype: classic autosomal dominant HCM sarcomeric mutations, defective cellular 
energy-sensing machinery, autosomal recessive Friedreich ataxia, and genetic 
morphologically and functionally disordered mitochondria. 
 Passive viscoelastic properties of human HCM cardiomyocytes are similar to those of 
normal hearts and so cannot account for increased stiffness of HCM hearts38. Diastolic 
relaxation is a highly energy-dependent process; diastolic dysfunction owing to impaired 
relaxation is the most common phenotypic physiological abnormality in patients with HCM33, 
and diastolic dysfunction has been associated with abnormal energetics in experimental 
models of HCM9,34,35. The additional demonstration of diastolic dysfunction in HCM 
phenocopies and in Friedreich ataxia36,37 has driven development and acceptance of the 
theory that energetic impairment, hypertrophy, and diastolic dysfunction are causally 
linked23.  
An alternate explanation is that mutant myofilament Ca2+ sensitivity directly causes 
diastolic dysfunction, and desensitization has been shown to improve it31. Studies in 
phosphorylation-deficient MYBPC3 mice suggest an important role for protein kinase A-
mediated phosphorylation of this protein to enhance lusitropy39. The enhanced late Na+ 
current observed in HCM increases cytosolic Ca2+, which increases cross-bridging and 
directly slows diastolic relaxation40.  
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[H1]Systolic dysfunction  
[H2] At rest 
If energy insufficiency is a feature of HCM, why is it not manifest as resting systolic 
dysfunction on echocardiography? Ejection fraction is normal or hyperdynamic in HCM, 
except infrequently in the 2% of patients who develop transformation into LV hypokinesia 
owing to diffuse fibrosis.61  A disparity often exists between the macroscopic assessment of 
global ejection fraction in patients with HCM who have decreased diastolic volumes, and the 
more granular assessment of decreased systolic strain even at rest. Reduced systolic strain is 
commonly detected both with echocardiographic speckle-tracking and using cardiac MR in 
patients with HCM, and correlates with the extent of exercise impairment even in 
nonobstructed patients41. van Dijk et al. found normal global systolic function in patients 
with impaired cardiomyocyte peak force generation and blunted length-dependent activation 
(Frank–Starling mechanism) in patients with MYBPC3 mutations7. Hypokinetic sarcomeres 
were found in these patients with normal macroscopic LV systolic function, irrespective of 
the four different mutations studied7. Thus, subclinical systolic LV dysfunction at rest is 
common in HCM; the underlying substrate for load-induced dynamic systolic dysfunction is 
present even when there is normal global function at rest. 
 
[H2] After exercise 
Further evidence of latent dynamic systolic dysfunction can be elicited in some patients with 
HCM after exercise. During exercise, regional and global systolic wall-motion abnormalities 
can occur in patients with either obstructive or nonobstructive HCM, in the absence of 
epicardial coronary disease42-44. The question of whether exercise-induced wall-motion 
abnormalities occur because of energy depletion from inefficient utilization or owing to 
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microvascular ischaemic disease leading to impaired ATP generation is controversial, and is 
discussed in detail below. Until recently, in vivo assessment of high-energy phosphate stores 
were performed at rest for technical reasons. Dass et al. studied 35 patients with HCM (of 
varying genotypes) with a resting outflow gradient <30 mmHg and matched controls, 
performing MR spectroscopy before and during leg-raise exercise inside the scanner45. As 
expected, the PCr/ATP ratio was lower at rest in patients with HCM. With exercise, the ratio 
dropped a further 8 ± 17% in patients, but not in controls. The resting energetic impairment 
did not correlate with the extent of hypertrophy, and only weakly with late gadolinium 
enhancement. 
 
[H2] With imposition of afterload 
Three phenomena, with features unique to HCM, illustrate the vulnerability of the energy 
inefficient myocardium to the imposition of obstruction and afterload: the mid-systolic drop 
in LV ejection velocities, apical aneurysm formation in mid-cavity obstruction, and rarely, 
profound systolic hypokinesia, or in extreme cases, cardiogenic shock when latent 
obstruction becomes persistent and severe. 
 
[H3] The ‘lobster claw abnormality’ 
In patients with HCM and a LVOT gradient ≥60 mmHg, an abnormal Doppler ejection 
velocity pattern occurs in the left ventricle, just below the tips of the mitral valve leaflets and 
also, therefore, below the site of LVOT obstruction. This phenomenon has been termed the 
‘lobster claw abnormality’ because of its characteristic appearance46 (FIG. 1). Early in 
systole, when the left ventricle is unimpeded, LV ejection velocities are normal (FIG. 2a). 
Simultaneously with mitral–septal contact, an abrupt reduction in ejection velocities occurs 
because of the sudden imposition of afterload (FIG. 2b). The mid-systolic reduction in 
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ejection velocities is reversed when outflow obstruction is alleviated or abolished47,48. The 
drop in velocities explains some of the well-recognised clinical features of HCM, for example 
the biphasic carotid pulse and mid-systolic closure of the aortic valve49. Conklin and 
colleagues extended this observation by measuring flow in the proximal descending aorta by 
Doppler echocardiography and showed an exacerbation of the reduction in flow after 
administration of dobutamine50. The appearance of the mid-systolic drop in velocities can 
vary between patients and from hour to hour depending on the severity of the outflow 
gradient, and the capacity of the left ventricle to overcome the obstruction48. However, the 
timing of the nadir always moves precisely in synchrony with timing of the peak velocity of 
the continuous-wave Doppler in the outflow tract and, therefore, with peak afterload46. 
Breithardt et al. used tissue Doppler imaging to record a similar drop in systolic myocardial 
velocities with obstruction51. This observation demonstrates that the lobster claw abnormality 
is not merely a flow phenomenon, but is caused by myocardial dysfunction (FIG. 3). Barac 
and colleagues also showed premature termination of septal contraction with obstruction that 
was reversed by abolition of obstruction47. 
 Ross explained the concept of afterload mismatch as the inability of the left ventricle 
to “…maintain a normal stroke volume against the prevailing systolic load on the left 
ventricle, and it generally occurs in the setting of limited preload reserve.”52.  Afterload 
mismatch was Ross’s term to explain the rapid recovery of poorly contracting myocardium 
after relief of outflow obstruction in aortic stenosis52. At the time, the actual mechanics of 
this phenomenon at the myocardial level were unknown. Increasing evidence now shows that 
aortic stenosis can cause severe energetic insufficiency that is mediated by increased 
afterload and is normalized after aortic valve replacement. Subclinical LV impairment can be 
demonstrated during stress, and this impairment responds to surgical correction53-56. Ross 
contrasted afterload mismatch in aortic stenosis to patients with irreversibly depressed 
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myocardial contractility, whose true (low) ejection fraction is unmasked by correction of the 
(usually mitral) regurgitation. 
 In HCM, LV performance can be doubly affected by energy inefficiency. Energy 
depletion can impair diastolic relaxation, which is nearly ubiquitous in HCM, and the effect 
of the acute imposition of afterload on an energy-depleted left ventricle reduces systolic flow. 
Together, diastolic and systolic dysfunction contribute to the observed inability to increase 
stroke volume with exercise, and thereby to symptoms of exercise intolerance and heart 
failure57. Energetic insufficiency can be genetic (HCM) or acquired (aortic stenosis), or be 
from a combination of both (obstructive HCM). 
 
[H3] Energy inefficiency or ischaemia? 
Is the mid-systolic drop in ejection velocities and flow simply due to ischaemia from 
microvascular disease, or to ischeamia from oxygen supply–demand mismatch? We argue 
that it is not due to either ischaemic cause.  First, there is the important clinical observation 
that angina at rest is uncommon in obstructive HCM. Secondly, substantial evidence indicates 
that resting ischaemia does not occur in patients with resting obstruction, as assessed using 
various techniques. 
 Cannon and colleagues assessed myocardial lactate consumption in the coronary 
veins. Myocardial lactate consumption at rest was normal, even in the presence of high 
resting gradients58,59. Lactate production did not occur until atrial pacing commenced58,59. 
Moreover, resting perfusion defects are not visualized on thallium scintigraphy in the great 
majority of patients60. Only 24% of patients had resting perfusion defects, and these patients 
had reduced resting systolic function owing to myocardial fibrosis in the end-stage phase of 
the disease61. Additionally, overall resting myocardial blood flow (assessed using PET and 
13N-labelled ammonia) did not differ between patients with HCM and controls (although the 
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vasodilator ‘reserve’, assessed using dipyridamole, was blunted)62. Accordingly, Crilley et al. 
showed that the myocardial perfusion reserve index in these patients did not correlate with 
energy impairment13. Carriers of the HCM-associated MYBPC3 mutation have reduced 
myocardial efficiency in the absence of hypertrophy and microvascular dysfunction63. 
Together with other findings17, Timmer and Knaapen concluded that “these results imply that 
impaired energetics are, at least in part, the direct result of ATP-wastage by mutated 
sarcomeres, and may precede coronary microvascular dysfunction in the pathophysiological 
cascade”22. 
 From this evidence, we believe that the mid-systolic reduction in LV Doppler ejection 
velocities, which is routinely and universally observed in patients with LVOT gradients of 
≥60 mmHg, is not caused by ischaemia, but by another phenomenon. We posit that 
inefficient utilization of energy in HCM is the cause. When ischaemia is superimposed on top 
of energetic impairment, the effects on systolic function and diastolic function are adversely 
synergistic, especially after exercise. 
 
[H3] Resting wall motion abnormalities  
Afterload-induced systolic dysfunction can trigger the occurrence of apical akinetic aneurysm 
in severe mid-LV obstruction, and heart failure and cardiogenic shock in the most extreme 
cases. In HCM with mid-LV obstruction, the LV apex can be subjected to very high 
impedance to ejection, which can lead to an apical akinetic aneurysm64. The same mid-
systolic drop in LV ejection velocities is seen just before the obstructing segment of the left 
ventricle (FIG. 4). The phenotype can be severe, with intrusive heart failure symptoms65,66, 
and ventricular arrhythmias can occasionally cause sudden death. The apical aneurysm 
increased the risk of thrombus formation and subsequent stroke or other systemic 
embolism66. These patients are difficult to manage, because symptoms are often refractory to 
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therapy, and they have a significantly worse prognosis than those with isolated apical 
hypertrophy. In mid-LV obstruction, though afterload mismatch begins the process of apical 
aneurysm formation, ischaemia owing to supply–demand mismatch and fibrosis can make 
dyssynergy irreversible. An interesting corollary might be seen in Takotsubo 
cardiomyopathy; evidence now shows that patients with this (in some ways phenotypically 
similar) syndrome have severe energetic impairment at presentation, as measured using 
31P-MR spectroscopy, and that metabolic abnormalities persist at 4-month follow-up67,68. 
 When patients with latent LVOT obstruction suddenly develop persistent severe 
obstruction, systolic wall-motion abnormalities can occur in segments that previously had 
normal wall motion. Resolution of LVOT obstruction precedes resolution of severe wall-
motion abnormalities. Cardiogenic shock is a rare complication of obstructive HCM and 
usually occurs in the context of reduced preload owing to dehydration. In patients with latent 
obstruction who suddenly develop a persistently high resting gradient, we have observed 
progressive LV systolic dysfunction and cardiogenic shock. Although some patients can be 
rescued with volume loading and negative inotropes69, we have seen several individuals in 
whom this spiral could be arrested only by surgical relief of obstruction70. These patients had 
systolic dysfunction that was disproportionate to the degree of ischaemia manifest on the 
electrocardiogram, and disproportionate to the minimal rise in cardiac biomarkers. Their 
syndrome reversed within minutes of surgical relief of LVOT obstruction (FIGS 5,6). 
Although we cannot exclude additional factors (such as catecholamine or other neurohumoral 
effects), we believe their dramatic presentation was caused by acute myocardial energy 
depletion — a concept supported by the rapid reversal after relief of obstruction. 
 
[H3] Normal and impaired responses to afterload  
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Is it possible that the mid-systolic drop in LV ejection velocities and flow is caused by 
obstruction alone, without HCM impaired energetics? Would normal individuals with normal 
left ventricles have the same degree of mid-systolic drop in the event of severe outflow 
obstruction? We cannot exclude this possibility. However, previous experiments argue in 
favour of intrinsic latent myocardial dysfunction having a role in the mid-systolic drop. 
Experiments in dogs with normal left ventricles showed that, after chronic aortic constriction, 
stroke volume returned towards normal.98,99  Moreover, after angiotensin administration to 
patients with a spectrum of LV dysfunction, stroke volume fell or remained constant only in 
those with compromised LV function96.  In patients with normal left ventricles stroke volume 
and stroke work increased. In another study of 12 control patients given low dose intravenous 
angiotensin there was no change in tissue Doppler echocardiographic velocities97. In contrast, 
21 non-obstructive HCM patients had a fall in tissue Doppler velocities even with small 
increases in afterload, including a drop in velocities in the non-hypertrophied posterior wall. 
“Systolic LV function is easily impaired by slight increases in afterload in patients with 
HCM”.97  These experimental observations are qualitatively similar to those observed by 
Barac and Breithardt in the course of gradient rise and fall.47,51 
  Compensation to afterload in the normal left ventricle is accomplished first by an 
increase in preload, dilatation of the left ventricle, and a Frank–Starling-mediated increase in 
contractility; this initial response is followed during the chronic phase by a compensated 
period marked by LV hypertrophy71.  In HCM, the capacity of the left ventricle to use preload 
as compensation can be compromised acutely and chronically because of impaired diastolic 
function, which could contribute to the observed instantaneous fall in LV stroke volume seen 
during the mid-systolic drop50. Abnormalities from sarcomeric mutations have been shown to 
affect LV contractile reserve. When isoproterenol was administered to mouse hearts with 
troponin T mutation-I79N an impaired responsiveness to inotropic stimulation was 
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demonstrated, along with worsening of diastolic function compared with normal controls72, 
and compared with a control troponin mutation with no effect on myofilament sensitivity. 
The investigators reviewed similar results with other models of sarcomeric HCM, and 
discussed how the findings could be explained by altered Ca2+ kinetics, including decreased 
energetics. In an earlier study using this mouse model of I79N mice, systolic function was 
increased relative to controls; however, the inotropic response to isoproterenol was impaired. 
The increase in LV fractional shortening was 9% vs 26% in controls 73. Also, four out of 13 
of the mice developed global hypokinesia and died. The investigators hypothesized that with 
increased Ca2+ sensitivity, the fibres might already be operating at the flat part of the force–
pCa relationship73. Energetic depletion could also explain this phenomenon. 
 The integrity of the Frank–Starling mechanism was evaluated in preparations from 
myectomy specimens of patients with five different HCM-related mutations of either thick or 
thin filaments. These experiments involved force measurements from single cardiomyocytes. 
Ca2+ sensitivity was demonstrated in all 38 patient samples and every mutation. Length-
dependent activation was lower in all HCM samples compared with donor samples. This 
impairment of the Frank–Starling mechanism was normalized when mutant troponin proteins 
were replaced with wild-type protein. Protein kinase A also increased phosphorylation of 
myosin-binding protein C and troponin I, and normalized length-dependent activation in the 
donors with sarcomere-negative HCM and truncating MYBPC3 mutations, but not in HCM 
caused by missense mutations74. The process of phosphorylation by protein kinase A requires 
ATP for catalysis and, therefore, might depend on energetic state. 
 In summary, though macroscopic LV systolic function may appear normal or even 
increased in HCM at rest, multiple imaging modalities, pulsed Doppler, tissue Doppler, strain 
echocardiography and CMR strain have shown subclinical systolic abnormalities at rest in 
non-obstructive HCM. Imposition of afterload in the form of LVOT obstruction (or in 
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experimental preparations by angiotensin) exacerbates dynamic systolic dysfunction. In light 
of the ample evidence of energetic depletion in HCM, even in non-obstructive disease, we 
have argued that spectrum of dynamic dysfunction-  the mid-systolic drop in LV ejection 
velocities, the nascent onset of aneurysms in mid-LV obstruction, and rarely shock are due to 
exacerbations of chronic energy depletion.   
 
[H1] Ventricular tachyarrhythmias 
Fractionation of paced ventricular electrocardiograms has been observed in patients with 
HCM who survive ventricular fibrillation, but not in those without ventricular fibrillation75. 
Clinically important ventricular arrhythmias can now be studied in patients with HCM using 
data from implanted cardioverter–defibrillators of patients who have had therapeutic 
discharges. In 230 recipients of implantable cardioverter–defibrillators, O’Mahony et al. 
analysed 56 ventricular arrhythmias from 29 patients76. The arrhythmia was monomorphic 
ventricular tachycardia in 86% of cases, ventricular fibrillation in 9%, and polymorphic 
ventricular tachycardia in 5%. Younger patients had shorter cycle length ventricular 
tachycardia, in keeping with the peak incidence of sudden cardiac death in younger patients 
and suggesting a genetic modifier of the re-entry circuit. The majority of ventricular 
tachycardia was monomorphic, and 67% was terminated by antitachycardia pacing76. In nine 
patients with sustained ventricular arrhythmia, Cha et al. found that more than half had 
monomorphic ventricular tachycardia, which frequently could be terminated (in 94% of 
patients) by pacing that interrupted re-entrant pathways77. 
 Sustained ventricular arrhythmias originate from two mechanisms. First, they 
originate from micro and macro re-entry. Second, they originate from abnormal automaticity, 
including triggered activity from early and late afterdepolarizations, and from enhanced 
pacemakers. 
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[H2] Re-entry 
Fibrosis is a common finding in HCM hearts, especially in patients who have died suddenly. 
Volumetric cardiac MR delayed hyperenhancement (expressed as a percentage of the LV 
mass) has been associated with sudden cardiac death or aborted sudden death events78. The 
relationship with fibrosis would seem to validate the re-entry mechanism as a cause for 
monomorphic ventricular arrhythmias in HCM. However, although fibrosis is fairly common 
in HCM hearts (occurring in 50%), sudden cardiac death is rare, occurring in only 1% per 
year2,3. Even in patients with a level of fibrosis of 15% of LV mass have a rate of sudden 
cardiac death or aborted sudden death of barely more than 1% per year. 78 
 
[H2] Abnormal automaticity 
Ventricular fibrillation or polymorphic ventricular tachycardia occurred in 14–44% of 
patients analysed after discharge from an implantable cardioverter–defibrillator76,77. These 
arrhythmias, especially if they occur without preceding premature ventricular contractions are 
likely to depend on abnormal automaticity. Cha et al. found clusters of ventricular arrhythmia 
in three patients with repeated, sustained ventricular arrhythmia, between four and 25 
repeated episodes in 5–120 min77. O’Mahony et al. observed clustered activity in four 
patients, between two and five episodes within 24 h76. These clusters might indicate that a 
trigger is acting on top of the underlying substrate, even in patients with re-entry. 
 Sinus tachycardia or atrial fibrillation have been observed immediately before the 
sustained ventricular arrhythmia in the majority of patients, suggesting a sympathetic drive to 
ventricular arrhythmia; tachycardia would also foster cytosolic Ca2+ accumulation and ATP 
depletion that would drive sustained ventricular arrhythmia77. Primary ventricular fibrillation, 
clustered ventricular tachycardia, and the ventricular fibrillation episodes, as well as 
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tachycardia before episodes, suggest that an enhanced automaticity trigger is acting on top of 
existing substrate. In HCM, potential triggers for ventricular arrhythmia are a change in the 
intracellular environment, either depletion of cytosolic energy stores, increased myofilament 
Ca2+ sensitivity, or cytosolic Ca2+ overload. 
 
[H3] Depletion of cytosolic energy stores 
Impairment of resting energetics, exacerbated during exercise, reduces the ATP available for 
energy-intensive processes elsewhere in the cell. The sarco/endoplasmic reticulum calcium 
ATPase (SERCA) hydrolyses ATP to transport Ca2+ from the cytosol into the sarcoplasmic 
reticulum. MR spectroscopy has shown that the levels of energetic depletion can compromise 
SERCA because of its extreme energy requirements8. Impaired function of this pump leads to 
increased cytosolic Ca2+ levels, which results in further Ca2+-induced Ca2+ release via 
activation of ryanodine receptors, potentially leading to malignant arrhythmias. By analogy, 
catecholaminergic polymorphic ventricular tachycardia is caused by a gain-of-function 
mutation in the ryanodine receptor gene. A 33% increase in calcium antagonist binding sites 
are demonstrated in the right atrial appendage of myectomy patients; these receptors were 
components of voltage-sensitive calcium channels; they are increased in parallel with 
increases in calcium flux.79 Increased catecholamine responsiveness has been reported80. 
 
[H3] Increased myofilament Ca2+ sensitivity 
Enhanced myofilament Ca2+ sensitivity is demonstrated by a left shift of the force–Ca2+ 
relationship. Ca2+ sensitization causes susceptibility to arrhythmias without remodelling, that 
is, without fibrosis or hypertrophy81. In mouse papillary muscles, myofibril Ca2+ sensitivity 
changes the shape of ventricular action potentials, induces greater beat-to-beat variability in 
action potential durations, and increases dispersion of conduction velocities at fast heart rates, 
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providing an arrhythmogenic substrate82. This enhanced arrhythmogenicity was blocked by 
blebbistatin, a myosin inhibitor that selectively reduces Ca2+ sensitivity. Linkage of the 
energy depletion and the Ca2+-sensitivity mechanisms was shown by Huke and colleagues83. 
Using a mouse model of troponin T I79N HCM, they showed that focal energy deprivation 
underlies ventricular arrhythmia susceptibility in mice with Ca2+-sensitized myofilaments. In 
this model, they found dephosphorylation (loss) of connexin-43 (gap junction α1 protein) that 
normally promotes gap-junction coupling85, with consequent focal slowing of conduction and 
a proarrhythmic state. ATP depletion was the mechanism for rapid connexin-43 
dephosphorylation. In this model, therefore, the two proposed pathophysiological effects — 
increased myofilament Ca2+ sensitivity and energy depletion — were linked. Sudden cardiac 
death in athletes during competition can reasonably be understood as an ‘energy crisis’ in this 
context12,84,83. 
 In a mouse models, desensitization to calcium as a result of gain-of-function 
mutations in myofilaments prevents development of the HCM phenotype31. The diastolic 
dysfunction and hypertrophy induced by the tropomyosin mutation, E180G (Tm180), with 
increased Ca2+ sensitivity, was reversed by desensitization. The investigators created a double 
transgenic mouse line, crossing Tm180 mice with mice expressing a pseudophosphorylated 
cardiac troponin I (S23D and S24D (TnI-PP); with reduced calcium sensitivity. Pathological 
hypertrophy did not occur in mice expressing both Tm180 and TnI-PP and LV performance 
was improved .  A small-molecule inhibitor of sarcomeric contractility (MYK-461) prevents 
HCM development in mice with a gain-of-function mutation in myosin92. 
 
[H3] Enhanced late Na+ current  
Investigators from Florence, Italy have highlighted abnormalities of cardiomyocytes from 
surgical specimens from patients undergoing myectomy. HCM cardiomyocytes showed 
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prolonged action potential duration owing to increased late Na+ and Ca2+ currents, and 
decreased repolarizing K+ current37. These abnormalities led to increased, prolonged Ca2+ 
transients, higher diastolic Ca2+ concentration, early and delayed afterdepolarizations, and 
arrhythmogenicity. The investigators found increased activity of calmodulin, a calcium-
binding messenger protein, that underlies increased phosphorylation of the L-type calcium 
channel, phospholamban, the ryanodine receptor, and the late Na+ channel in the HCM 
specimens. Sustained activation of calmodulin is driven by increased cytosolic Ca2+ 
concentration37. 
 Ranolazine partially reversed the increase in the late Na+ current, shortened action 
potential duration, and decreased the frequency of afterdepolarizations37. A novel late Na+ 
channel-inhibiting agent Eleclazine is currently under investigation in a multicentre trial86,94. 
Although its capacity to increase exercise oxygen consumption through a lusitropic effect is 
the primary end point, an important secondary end point is the effect of this drug on 
ventricular arrhythmias assessed using a 30-day monitor82. 
 Ventricular arrhythmias are the cause of SCD in HCM, and the prevention of SCD 
has assumed a central role in HCM clinical care1-3. At this time the widely applied method for 
SCD prevention is the implanted defibrillator; but current risk stratification guidelines have 
low sensitivity and specificity 2,3. This may lead to sudden deaths in patients who have not 
been implanted, and implantation of ICDs in patients who never have appropriate discharges. 
In addition, sudden deaths are rare, as well, in patients who have had successful myectomy1  
but such patients constitute a minority of patients with high risk profiles. It is hoped that an 
understanding of the basic pathways leading to ventricular arrhythmias will lead to biological 
treatments to prevent such deaths, and someday preclude the need for ICDs in many patients.  
A summary of the known pathophysiological mechanisms underlying development of the 
HCM phenotype is shown in FIG. 7.  
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[H1] Treatment of energy depletion 
In the modern era, specific pathophysiological HCM derangements have been targeted in the 
preclinical realm, and trials are beginning in patients15,87,88. Targeting cellular energetic 
impairment is a promising paradigm in HCM. If substrate utilization can be made more 
efficient and save more energy, then improved contractile reserve results from the same 
conditions. Various therapeutic agents affect myocardial metabolic pathways87 and might 
prove useful in HCM. Therapeutic efforts in this area are in their infancy, but a positive 
clinical trial has been published89. 
 A total of 46 patients with symptomatic, nonobstructive HCM were randomly 
assigned in a double-blind manner to perhexiline (a metabolic modulator or placebo89. 
Perhexiline has pleiotropic actions including inhibition of long chain fatty acid uptake into 
the mitochondria by inhibition of carnitine O-palmitoyltransferase 1. In a mouse model of 
HCM, perhexiline therapy resulted in a metabolic shift from fatty acids to glucose90. Energy 
obtained during glucose oxidation requires less oxygen consumption than fatty acid 
metabolism, enhancing cardiomyocyte energy efficiency. Despite the lack of LV outflow 
gradient, patients with HCM had a markedly reduced exercise capacity (peak VO2) compared 
with matched healthy controls, and also had impaired diastolic function measured using 
tissue Doppler imaging. Participants were followed up for a mean of 16 weeks of therapy. 
The perhexiline group showed a significant increase in peak VO2 (the primary end point), and 
in functional class and quality of life. The heart-rate-normalized time to peak filling (nTTPF), 
a sensitive marker of early LV filling, was measured using radionuclide ventriculography at 
rest and during exercise. Whereas healthy controls showed a shortening of nTTPF on 
exercise, patients with HCM showed an abnormal lengthening, which indicates a profound 
impairment of (energy-dependent) LV active relaxation on exercise. This abnormal response 
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was almost normalized with perhexiline, which was associated (presumably causally) with a 
significant improvement in the cardiac energetic impairment (an increase in PCr/ATP ratio).  
 Other metabolic agents are being investigated in HCM, although these studies are in 
an early phase. Trimetazidine is being evaluated in a phase IIb clinical trial91 of symptomatic 
patients with nonobstructive HCM, to assess a primary end point of peak VO2. 
 A small-molecule inhibitor of sarcomeric contractility (MYK-461) suppresses HCM 
development in mice with a gain-of-function mutation in myosin, in parallel with reductions 
in fractional shortening and ATPase activity92. The investigators compared gene expression 
of proteins localized to the mitochondria and found dysregulated gene expression in 20% of 
genes in R403Q mice and 29% of genes in R453C mice compared with wild type.Early 
treatment of these mice with MYK-461 reduced the percentage of dysregulated mitochondrial 
genes to 4% and 8%, respectively. These data demonstrated that correction of gain of 
function at the myofilament level resulted in a normalized cellular metabolic state. This 
improvement might stem from more efficient energy utilization and less substrate depletion, 
or directly from correction of the myofilament gain of function. 
 
[H2] Inhibition of the late Na+ current 
Ranolazine has pleiotropic effects, including inhibition of the late Na+ current. A study of its 
use in cardiomyocytes obtained from myectomy showed beneficial effects on the 
contraction–relaxation cycle, which were attributed to improvements in Ca2+ signalling rather 
than a metabolic effect40,93. The novel agent GS-6615, which inhibits the late Na+ current, is 
currently under investigation in the multicentre LIBERTY-HCM trial86,94. A pilot trial 
investigated whether oral diltiazem attenuated disease progression in patients with preclinical 
HCM and an identified genetic mutation. 95. LV end-diastolic diameter improved towards 
normal in the diltiazem group but decreased further in controls 
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[H2] Potential future applications 
The mid-systolic drop reflects a ‘tug-of-war’ between the contractile force of the left 
ventricle and the afterload imposed by obstruction. Its extent, the percent drop to the nadir, 
and the absolute velocity of the nadir, might be used to assess the inotropic state of the left 
ventricle to any given magnitude of gradient, longitudinally, and in response to therapy. The 
mid-systolic drop could act as a biomarker of contractile reserve. Currently, clinical 
application of metabolic resonance spectroscopy is limited by long acquisition times and low 
applicability of the technique for individual patients. Improved and shorter protocols, as well 
as developments allowing measurement of abnormal metabolic flux (rather than steady state 
levels of metabolites) might increase the clinical relevance of this technique. In the future, the 
magnitude of energetic impairment might provide prognostic information in both heart failure 
and sudden death. Otherwise MR spectroscopy might be used to identify which patients with 
mid-LV obstruction are at highest risk for future apical aneurysm, or inform counselling of 
individual patients about intense exercise, which is a challenging area with limited evidence. 
Finally, the concept of energetic insufficiency as a central mechanism in the pathophysiology 
of obstructive and nonobstructive HCM opens up new areas for potential pharmacological 
intervention, particularly for patients with nonobstructive disease, for whom current 
therapeutic options for relief of severe symptoms are very limited. 
 
[H1] Conclusions 
Energetic insufficiency can be genetic (HCM) or acquired (aortic stenosis) or result from a 
combination of both (obstructive HCM). Energy depletion in HCM, and in its phenocopies, 
explains a wide variety of phenotypic abnormalities. In nonobstructive HCM, preliminary 
evidence from a clinical trial indicates that improving myocardial energetics improves 
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rigorously-measured exercise tolerance and also symptoms. In obstructive HCM, energy 
depletion might best explain the echocardiographic mid-systolic drop in LV ejection 
velocities and flow. This abnormality is characteristic of underlying, clinically inapparent LV 
impairment at rest that is exacerbated by exercise, and especially by afterload. 
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Figure 1 | Mid-systolic drop in ejection velocities. a | The ‘lobster claw abnormality’ is the 
mid-systolic drop in left ventricular ejection velocities, seen with pulsed Doppler 
echocardiography at the entrance to the left ventricular outflow tract (LVOT) in a patient with 
a 90 mmHg LVOT systolic gradient owing to mitral–septal contact. The mid-systolic drop 
(white arrow) is caused by the sudden imposition of afterload from mitral–septal contact in 
patients with hypertrophic cardiomyopathy and a LVOT gradient >60 mmHg. The feature is 
direct evidence of the effect of gradient in obstructive HCM; we posit that it is caused by 
afterload mismatch caused by myocardial energy depletion. b | The same patient after 
disopyramide and abolition of the gradient. Note that the mid-systolic drop in ejection 
velocities is no longer present.  
 
Figure 2 | LV Ejection velocities in early systole and mid-systole in obstructive HCM. a | 
Early systole before mitral–septal contact. Pulsed Doppler at entrance of left ventricular 
outflow tract. Mid and late systole is shaded on the second trace. Early systolic unobstructed 
flow occurs before mitral–septal contact (arrows). b | Before mitral–septal contact, flow 
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courses around the septum and catches the anteriorly displaced mitral valve and sweeps it 
into the septum. The chordae and papillary muscles act to posteriorly restrain the mitral 
valve. c | After mitral–septal contact. Early systole is shaded on the second trace. The 
beginning of the mid-systolic drop occurs at the onset of mitral–septal contact, and the abrupt 
increase in afterload. The nadir of the drop occurs simultaneously with the peak of the 
continuous wave Doppler gradient and peak afterload (arrow)46,48. d | The mid-systolic drop 
is caused by afterload mismatch between the impedance of obstruction and left ventricular 
contractility.  
 
Figure 3 | ECG, invasively-measured LVOT pressure gradient, and TDI velocity trace 
from the basal septum. Note the simultaneous development of the left ventricular outflow 
tract (LVOT) gradient (open arrow) and the mid-systolic septal deceleration notch (solid 
arrow). ECG electrocardiogram; LV left ventricular; TDI tissue Doppler imaging. Reprinted 
from Breithardt, O.-A. et al. Mid systolic septal deceleration in hypertrophic 
cardiomyopathy: clinical value and insights into the pathophysiology of outflow tract 
obstruction by tissue Doppler echocardiography. Heart 91 (3), 379–380 (2005), with 
permission from BMJ Publishing Group Ltd.  
 
Figure 4 | Apical aneurysm in mid-LV obstruction. a | Pulsed Doppler at the entrance of 
the obstructing neck of mid-left ventricular (LV) obstruction showing the mid-systolic drop 
in LV ejection velocities. Trapped blood escapes only from the aneurysm in early diastole. 
Thin arrow points to the nadir of the mid-systolic drop, and thicker arrow indicates the onset 
of virtually complete mid-LV obstruction. b | Systolic frame from LV cineangiogram of a 
patient with severe mid-LV obstruction (arrows). There were high resting mid-LV systolic 
pressure gradients and an apical akinetic aneurysm. We propose that afterload mismatch 
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initiates aneurysm formation; then ischemia and afterload mismatch act in concert to increase 
its size. Panel a reprinted from Sherrid, M. V. et al. Reflections of inflections in hypertrophic 
cardiomyopathy. J. Am. Coll. Cardiol. 54 (3), 212–219 (2009), with permission from 
Elsevier. Panel b reprinted from Po, J. R. F. et al. Doppler systolic signal void in 
hypertrophic cardiomyopathy: apical aneurysm, and severe obstruction without elevated 
intraventricular velocities. J. Am. Soc. Echocardiogr. 28 (12), 1462–1473 © (2015), with 
permission from Elsevier.  
 
Figure 5 | Acute heart failure and shock. 2D echocardiograms performed on admission to 
the emergency department in a patient with previously diagnosed hypertrophic 
cardiomyopathy and latent obstruction. Patient had developed refractory cardiogenic shock 
after a diarrhoeal illness. Hypotension did not respond to copious fluids, intravenous 
β-blockade, and phenylephrine. a | Parasternal long-axis frames showing the septal bulge 
(wide arrow), mitral–septal contact (thin arrow), and systolic septal dyskinesia (arrowheads). 
b | Mid-left ventricular short-axis frames showing diffuse akinesia with mid-anterior septal 
and anterior dyskinesia. c | Apical four-chamber frames showing the septal bulge (wide 
arrow) and mitral–septal contact (thin arrow). There is apical and mid-left ventricular 
dilatation, and severe hypokinesia of the apical and mid-left ventricular segments, but 
preservation of basilar wall motion. Doppler left ventricular outflow gradient was 90 mmHg. 
d | Cardiac catheterization shows peak-to-peak systolic gradient of 70 mmHg. Coronary 
arteries were normal. Reprinted from Sherrid, M. V. et al. Reversal of acute systolic 
dysfunction and cardiogenic shock in hypertrophic cardiomyopathy by surgical relief of 
obstruction. Echocardiography 28 (9), E174–E179 (2011), with permission from XXX.  
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Figure 6 | Postoperative echocardiogram performed 4 months later. The format is the 
same as in FIG. 5. A bioprosthetic mitral valve is now present and myectomy has been 
performed to thin the septum. a | Parasternal long-axis frames showing no left ventricular 
outflow tract obstruction. The septum is thinned and there is normalization of septal and 
posterior wall motion. b | Mid-left ventricular short-axis frames showing normal wall motion. 
c | Apical four-chamber frames showing normalization of the left ventricular dilatation and 
normalization of wall motion in the apical and mid-left ventricular segments. Doppler 
showed no left ventricular outflow gradient. Reprinted from Sherrid, M. V. et al. Reversal of 
acute systolic dysfunction and cardiogenic shock in hypertrophic cardiomyopathy by surgical 
relief of obstruction. Echocardiography 28 (9), E174–E179 (2011), with permission from 
XXX.  
 
Figure 7 | Three proposed central pathophysiological pathways for development of 
hypertrophic cardiomyopathy phenotype in genetic hypertrophic heart disease. 
Inefficient utilization of energy by mutant myofilaments leads to energy depletion (detected 
in patients as a decreased phosphocreatine [PCr]/ATP ratio). Energy depletion is also 
observed in phenocopies: 5′-AMP-activated protein kinase (AMPK) mutations, Friedreich 
ataxia, and mitochondrial mutations. Energy depletion pathway (shown with black arrows) 
results in impaired function of sarco/endoplasmic reticulum calcium ATPase (SERCA, 
because of its high obligate energy requirements) leading to decreased diastolic uptake of 
Ca2+ and cytosolic Ca2+ overload. In an adverse feedback loop, elevated Ca2+ level impairs 
the ryanodine receptor leading to even higher diastolic Ca2+ levels and ventricular 
arrhythmias. Energy depletion results in latent global left ventricular dynamic systolic 
dysfunction, of which the characteristic abnormality is the mid-systolic drop in ejection 
velocities when obstruction afterload is interposed, although exercise can provoke a 
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hypokinetic response even in nonobstructed patients. Increased cytosolic Ca2+ can lead to 
ventricular arrhythmias regardless of the mechanism. Diastolic function is highly energy-
dependent and energy depletion is associated with impaired relaxation in sarcomeric 
hypertrophic cardiomyopathy and the phenocopies. Myofilament Ca2+ sensitivity (green 
arrows) directly causes inefficient energy utilization and depletion, directly impairs diastolic 
function, and is arrhythmogenic. Increased cytosolic Ca2+ can signal upregulated transcription 
through mediators of calmodulin (calcium/calmodulin-dependent protein kinase II; CaMKII) 
or calcineurin. Ca2+ overload acting through calmodulin (red arrows) enhances late 
Na+ channel and cytosolic Na+, which — through the reciprocal exchange pumps in the 
sarcoplasmic reticulum and cell membrane — results in Ca2+ overload.  
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